Orai3 is selectively required in MCF-7 cells, it is a contributor in SOCE in ER+ but not in ER- breast cancer cells and silencing Orai3 results in reduced proliferation, decrease in anchorage-independent growth and decreased xenograft development in-vivo [38,39,40,41]. This evidence concerns the gene ORAI3 and breast carcinoma.